Generating Sustainable, Stable Business Revenue
First written in FY2023. 1 of 2 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2021: 1 of 11 companies on the "Worse" side.
7 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「As before, we aim to achieve sustainable and stable business growth and revenue by advancing each ongoing joint drug-discovery research project and steadily concluding new agreements.」
The company has reaffirmed its policy of pursuing sustainable, stable business growth and revenue through progress in existing research and the acquisition of new agreements. - FY2023First statedAnnual report
「By appropriately identifying and responding to the needs of pharmaceutical companies with which we have business partnerships in mRNA-targeted small-molecule drug discovery, we aim to advance joint drug-discovery research without disruption and generate sustainable and stable business revenue by connecting its results to business partnerships with new pharmaceutical companies.」
The company seeks to stabilize revenue through a cycle of advancing research with existing partners and using the results to establish new partnerships.